scholarly journals O-11 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)

2020 ◽  
Vol 31 ◽  
pp. 235
Author(s):  
K. Yamaguchi ◽  
Y. Bang ◽  
S. Iwasa ◽  
N. Sugimoto ◽  
M. Ryu ◽  
...  
Keyword(s):  
Gastroesophageal Junction ◽  
Phase 2 ◽  
Her2 Positive ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Gastroesophageal Junction Adenocarcinoma ◽  
O 11 ◽  
Randomized Phase 2

scholarly journals RBTT-01. RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA

2018 ◽  
Vol 20 (suppl_6) ◽  
pp. vi234-vi234 ◽  
Author(s):  
Manmeet Ahluwalia ◽  
David Peereboom ◽  
Cathy Schilero ◽  
Deborah Forst ◽  
Eric Wong ◽  
...  
Keyword(s):  
Low Dose ◽  
Standard Dose ◽  
Recurrent Glioblastoma ◽  
Phase 2 ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Randomized Phase 2

A randomized phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. TPS4133-TPS4133 ◽  
Author(s):  
Kensei Yamaguchi ◽  
Yung-Jue Bang ◽  
Daisuke Sakai ◽  
Hisateru Yasui ◽  
Yoshinori Kawaguchi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase 2 ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Randomized Phase 2

scholarly journals Multifocal ERG and Microperimetry Changes in Response to Ranibizumab Treatment of Neovascular AMD: Randomized Phase 2 Open-Label Study

2020 ◽  
Vol Volume 14 ◽  
pp. 3599-3610
Author(s):  
Masumi G Asahi ◽  
Josh Wallsh ◽  
Spencer M Onishi ◽  
Shari Kuroyama ◽  
Ron P Gallemore
Keyword(s):  
Multifocal Erg ◽  
Phase 2 ◽  
Neovascular Amd ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Randomized Phase 2 ◽  
Ranibizumab Treatment
Sign in / Sign up

Export Citation Format

Share Document